Malignant Solid Tumors
27
10
10
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
7%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (27)
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
A Study of TAK-505 in Adults With Solid Tumors
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The Effect of Serum Ferritin in irAE
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas